Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology

When Do People With ARSACS Start Using a Wheelchair?

At a Glance

People with ARSACS typically transition to using a wheelchair between their late 20s and 40s, though the exact timeline depends on their specific SACS gene mutation. Transitioning is a gradual process that helps conserve physical energy, prevent dangerous falls, and maintain independence.

The timeline for needing a wheelchair in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) varies greatly from person to person. Historically, many people with the classic form of ARSACS transition to using a wheelchair for most of their mobility between their late 20s and 40s. However, because there are hundreds of different mutations in the SACS gene (the gene responsible for ARSACS), some people may need a wheelchair as early as their late 20s [1], while others remain independently walking well into their 50s. Rather than a sudden loss of walking ability, the transition to a wheelchair is typically a gradual process that involves using aids like canes or walkers first [2][3].

How ARSACS Affects Walking Over Time

ARSACS is characterized by a triad of symptoms that combine to make walking progressively more difficult and energy-intensive [4][5]. These include:

  • Cerebellar ataxia: This causes poor balance, coordination issues, and an unsteady gait. This physical risk often leads to a profound “fear of falling,” which can cause significant anxiety when navigating your environment [6][2].
  • Spasticity: Increased muscle stiffness, especially in the legs, makes movements feel heavy and stiff [6].
  • Peripheral sensorimotor neuropathy: Nerve damage in the legs and feet causes weakness and decreased sensation, making it harder to feel the ground [5][7].
  • Visual Changes: ARSACS is frequently associated with specific retinal abnormalities (thickening of retinal nerve fibers). While not causing blindness, these visual changes can compound balance issues and make it harder to safely navigate uneven terrain [8][9].

These factors compound over time. As the condition progresses, individuals often find that walking requires an immense amount of concentration and physical effort [10].

Genetic Differences and the Timeline

The specific mutation you have in the SACS gene plays a significant role in how quickly symptoms progress [11].

  • The Quebec Founder Mutation: In regions where ARSACS is most common (like Quebec, Canada), a specific “founder mutation” leads to a more predictable timeline, with wheelchair use often beginning in the 30s or 40s.
  • Non-Quebec Mutations: Outside of Quebec, mutations in the SACS gene are incredibly diverse, leading to what doctors call phenotypic variability (differences in how the disease looks and progresses) [12][13]. Because of this genetic diversity, it is harder to predict exactly when someone will need a wheelchair [14][15]. Some individuals with atypical mutations have very little spasticity, which can change the timeline for mobility loss [16][17].

Proactive Management and Knowing When to Transition

You are not a passive victim to this timeline. Proactive management with your medical team can help optimize and preserve your walking ability for as long as safely possible [18]:

  • Physical and Occupational Therapy (PT/OT): Working with therapists is crucial. They can design safe stretching routines to combat spasticity and gait-training exercises to improve balance.
  • Spasticity Management: Your neurologist may prescribe medications that help relax muscle stiffness, making walking more comfortable.
  • Professional Fitting: When it is time for a cane or walker, do not just buy one online. A PT or OT should assess your specific gait and correctly fit you for the right device to ensure it actually prevents falls rather than causing them.

Signs it might be time for a mobility aid:

  • You are skipping social events or outings because you are worried about fatigue or the walking distance.
  • You are falling, stumbling, or losing your balance more than once a week.
  • You have to hold onto walls or furniture to move around your home safely.

Re-framing the Wheelchair

Many newly diagnosed patients fear the idea of a wheelchair and view it as “giving up.” However, in the context of ARSACS, a wheelchair is a vital medical tool that can dramatically improve your quality of life [19].

  • Energy Conservation: Walking with ataxia and spasticity uses a tremendous amount of energy. Using a wheelchair for longer distances saves your energy for things you enjoy, rather than exhausting yourself just getting from point A to point B [10][2]. You can also start conserving energy early by using tools like a shower chair or a stool while cooking.
  • Fall Prevention: As balance decreases, the risk of serious falls increases [3]. A wheelchair provides a safe way to move around without the constant fear or risk of injuries like fractures or head trauma.
  • Maintaining Independence: Rather than restricting you, a wheelchair or motorized scooter can expand your world, allowing you to participate in social events, travel, and run errands safely and independently [19].

Crucially, using a wheelchair for distance or energy conservation does not mean you have to stop walking entirely. Many patients use a wheelchair for community outings but continue to practice walking exercises in safe, controlled environments with their physical therapist.

Common questions in this guide

At what age do people with ARSACS usually need a wheelchair?
The timeline varies significantly based on your specific SACS gene mutation. Individuals with the classic Quebec founder mutation often begin using a wheelchair between their late 20s and 40s. Those with atypical mutations may remain walking well into their 50s.
Why does ARSACS make walking so difficult?
ARSACS causes a combination of balance issues (ataxia), muscle stiffness (spasticity), and nerve damage (neuropathy) in the legs. As these symptoms progress and compound over time, walking requires an immense amount of concentration and physical effort.
How can I preserve my ability to walk with ARSACS for as long as possible?
Working proactively with physical and occupational therapists is essential. They can design safe stretching routines to manage muscle stiffness, provide gait-training exercises to improve balance, and properly fit you for mobility aids like canes or walkers.
How do I know it is time to transition to a wheelchair?
It may be time to consider a wheelchair if you are falling frequently, having to hold onto furniture to navigate your home, or skipping social events because you are worried about fatigue. A physical or occupational therapist can evaluate your mobility and help you safely transition.
Will I have to stop walking completely once I get a wheelchair?
Not at all. Many people with ARSACS use a wheelchair for long distances or community outings to conserve energy, but continue to practice walking exercises in safe, controlled environments with their physical therapist or walk short distances at home.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific SACS mutation do I have, and what is known about its typical progression and how it might affect my mobility timeline?
  2. 2.Can you refer me to a physical therapist or occupational therapist who specializes in ataxia to help me preserve my mobility and safely manage transitions?
  3. 3.Are there specific medications or therapies you recommend to manage my spasticity to make walking easier right now?
  4. 4.How do I know when it is clinically appropriate to transition from a cane to a walker, or a walker to a wheelchair?
  5. 5.When the time comes, how can we connect with a specialized seating clinic to ensure I am evaluated and fitted properly for a wheelchair?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) in a Thai Patient: The Classic Clinical Manifestations, Funduscopic Feature, and Brain Imaging Findings with a Novel Mutation in the SACS Gene.

    Srikajon J, Pitakpatapee Y, Limwongse C, et al.

    Tremor and other hyperkinetic movements (New York, N.Y.) 2020; (10()):1 doi:10.5334/tohm.68.

    PMID: 32775015
  2. 2

    Functional mobility in walking adult population with ataxia of Charlevoix-Saguenay.

    Lessard I, St-Gelais R, Hébert LJ, et al.

    Orphanet journal of rare diseases 2021; (16(1)):432 doi:10.1186/s13023-021-02054-2.

    PMID: 34649570
  3. 3

    Selection of Clinical Outcome Assessments for Trial Readiness in ARSACS - 2-year Progression and Responsiveness to Change Part 2: Mobility, Balance, and Lower Limb Coordination.

    Lessard I, Duchesne E, Hébert LJ, et al.

    Cerebellum (London, England) 2025; (24(4)):95 doi:10.1007/s12311-025-01849-4.

    PMID: 40332679
  4. 4

    Spastic ataxias.

    Bereznyakova O, Dupré N

    Handbook of clinical neurology 2018; (155()):191-203 doi:10.1016/B978-0-444-64189-2.00012-3.

    PMID: 29891058
  5. 5

    A novel hemizygous SACS mutation identified by whole exome sequencing and SNP array analysis in a Chinese ARSACS patient.

    Liu L, Li XB, Zi XH, et al.

    Journal of the neurological sciences 2016; (362()):111-4.

    PMID: 26944128
  6. 6

    ARSACS: Clinical Features, Pathophysiology and iPS-Derived Models.

    Salem IH, Blais M, Zuluaga-Sánchez VM, et al.

    Cerebellum (London, England) 2025; (24(1)):24 doi:10.1007/s12311-024-01777-9.

    PMID: 39753868
  7. 7

    Neuropathy in ARSACS is demyelinating but without typical nerve enlargement in nerve ultrasound.

    Kneer K, Straub S, Wittlinger J, et al.

    Journal of neurology 2024; (271(5)):2494-2502 doi:10.1007/s00415-023-12159-2.

    PMID: 38261029
  8. 8

    Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Parkinson MH, Bartmann AP, Clayton LMS, et al.

    Brain : a journal of neurology 2018; (141(4)):989-999 doi:10.1093/brain/awy028.

    PMID: 29538656
  9. 9

    Retinal Architecture in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): Insights into Disease Pathogenesis and Biomarkers.

    Rezende Filho FM, Bremner F, Pedroso JL, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(9)):2027-2035 doi:10.1002/mds.28612.

    PMID: 33893680
  10. 10

    From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Gagnon C, Brais B, Lessard I, et al.

    Orphanet journal of rare diseases 2018; (13(1)):165 doi:10.1186/s13023-018-0898-z.

    PMID: 30231904
  11. 11

    A novel homozygous SACS mutation identified by whole exome sequencing-genotype phenotype correlations of all published cases.

    Xiromerisiou G, Dadouli K, Marogianni C, et al.

    Journal of molecular neuroscience : MN 2020; (70(1)):131-141 doi:10.1007/s12031-019-01410-z.

    PMID: 31701440
  12. 12

    A Probable Korean Case of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Kwon KY, Huh K, Eun BL, et al.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2015; (42(4)):271-3 doi:10.1017/cjn.2015.38.

    PMID: 26153042
  13. 13

    SACS variants are a relevant cause of autosomal recessive hereditary motor and sensory neuropathy.

    Vill K, Müller-Felber W, Gläser D, et al.

    Human genetics 2018; (137(11-12)):911-919 doi:10.1007/s00439-018-1952-6.

    PMID: 30460542
  14. 14

    A novel SACS p.Pro4154GlnfsTer20 mutation in a family with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Samanci B, Gokalp EE, Bilgic B, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(7)):2969-2973 doi:10.1007/s10072-021-05117-1.

    PMID: 33559790
  15. 15

    Clinical and molecular studies in two new cases of ARSACS.

    Ricca I, Morani F, Bacci GM, et al.

    Neurogenetics 2019; (20(1)):45-49 doi:10.1007/s10048-019-00564-7.

    PMID: 30680480
  16. 16

    Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay without Spasticity.

    Aida I, Ozawa T, Fujinaka H, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(24)):3963-3967 doi:10.2169/internalmedicine.7401-21.

    PMID: 34121011
  17. 17

    Early-onset axonal Charcot-Marie-Tooth disease due to SACS mutation.

    Souza PVS, Bortholin T, Naylor FGM, et al.

    Neuromuscular disorders : NMD 2018; (28(2)):169-172 doi:10.1016/j.nmd.2017.11.008.

    PMID: 29277257
  18. 18

    Jiao's style scalp acupuncture combined with physiotherapy for autosomal recessive spastic ataxia of Charlevoix-Saguenay type: A case report.

    Sng KS, Sin YS, Alhawiti SMO

    Heliyon 2024; (10(12)):e33046 doi:10.1016/j.heliyon.2024.e33046.

    PMID: 39005899
  19. 19

    Efficacy of Manual Wheelchair Skills Training for Improving Skills and Confidence in People With Hereditary Degenerative Disorders: Protocol for a Sequential Multimethods Study.

    Niyomwungere E, Routhier F, Gagnon C, et al.

    JMIR research protocols 2025; (14()):e66974 doi:10.2196/66974.

    PMID: 40742628

This page is for educational purposes regarding ARSACS mobility timelines. Always consult your neurologist, physical therapist, or occupational therapist for personalized advice on mobility aids and physical transitions.

Get notified when new evidence is published on Autosomal recessive spastic ataxia of Charlevoix-Saguenay.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.